Latest News

Chen Liu, MD, PhD, Chair of the Yale Department of Pathology, recently announced the 2021 Faculty Promotions. The 2021 promotion cycle included Natalia Buza, MD, Professor of Pathology, and Themis Kyriakides, PhD, Professor of Pathology, Paul Cohen, MD, Associate Professor of Pathology, Peter Gershkovich, MD, MHA, Associate Professor of Pathology, and Kurt Schalper, MD, PhD, Associate Professor of Pathology.

The landscape of immunotherapy biomarkers is rapidly evolving, and future developments are likely to have an impact on patients and clinicians alike, said Kurt A. Schalper, MD, PhD, in a virtual presentation during the 5th Annual International Congress on Oncology and Pathology.

The award — granted to just 5% of NIH-funded investigators —ensures that Kurt Schalper’s research will be funded for the next seven years. It supports his groundbreaking work identifying novel pathways for cancer immunotherapy which can be used to optimally select and treat patients with non-small cell lung cancer.

In a new study, Yale Cancer Center scientists suggest that as the number of clinical trials in cancer immunotherapy grows exponentially, some caution should be exercised as we continue to better understand the biology of these new therapeutic targets.

The methods and equipment used to probe cellular questions are rapidly advancing—including, at Yale, through the addition in 2014 of CyTOF, or Cytometry Time-Of-Flight, and this past June of the CyTOF Imaging Mass Cytometer (IMC), which greatly expands Yale's ability to examine specimens that are analyzed both for clinical diagnosis and for basic research.

Yale Cancer Center will join a group of prominent cancer research and treatment institutions in a new Stand Up To Cancer (SU2C) – American Cancer Society $20 million Dream Team to combat lung cancer.

A Yale-led team of researchers has developed a new assay, or investigative tool, to measure the anti-tumor immune activity in non-small cell lung cancer tumors that could lead to a more accurate determination of which patients will respond to immune therapy drugs. Findings from the study were published in the Journal of the National Cancer Institute.